Dr. Suresh Ramalingam on Immune Checkpoint Inhibitors in NSCLC Treatment
Dr. Suresh Ramalingam on sequencing immune checkpoint inhibitors with chemotherapy in NSCLC treatment. He adds that a new class of agents can be given in conjunction with immune checkpoint inhibitors, such as IDO inhibitors.
Suresh Ramalingam, MD, director of Medical Oncology and Lung Cancer Program, Winship Cancer Institute of Emory University, on sequencing immune checkpoint inhibitors with chemotherapy in non-small-cell lung cancer (NSCLC) treatment. He adds that a new class of agents can be given in conjunction with immune checkpoint inhibitors, such as IDO inhibitors.
Ramalingam says that with recent developments in immune checkpoint inhibitors, community oncologists may see them move from second-line treatment in NSCLC to earlier treatments. He says this may help improve cure rates within the stages of metastatic disease.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
